Healthcare / MedTech
Johnson & Johnson / Stryker — M&A Valuation & Merger Model
Independent valuation and merger model for a hypothetical acquisition, including synergy analysis, accretion/dilution, and sector-specific risk adjustments.
- Company / Asset
- Johnson & Johnson / Stryker
- Sector
- Healthcare / MedTech
- Type of analysis
- M&A Valuation / Merger Modelling
- Published
- 2026
Executive overview
Independent M&A valuation and merger model built around a hypothetical acquisition of Stryker by Johnson & Johnson, applying triangulated valuation (comparable companies, precedent transactions, DCF) alongside a full merger model with synergy quantification and accretion/dilution analysis. The exercise incorporates sector-specific considerations, alongside sensitivity testing across financing mix and synergy realisation timing.
Key metrics
- Valuation methods3 (triangulated)
- Synergy buildBottom-up, phased
- EPS impact5-year accretion/dilution
- StructureFunding-mix sensitivities
Full analysis
View the complete report below or download the PDF.
Disclaimer
This website presents independent, self-initiated research and analytical work prepared for skills demonstration and educational purposes. It does not constitute investment advice, an offer, a solicitation or professional transaction advice. The author has not acted as an adviser to, or on behalf of, the companies referenced unless explicitly stated otherwise, and no analysis on this site is affiliated with, endorsed by or authorised by any named company. All analyses are based on publicly available information and personal assumptions, which may be incomplete or inaccurate. Company names and trademarks remain the property of their respective owners.
Independent work developed for illustrative and educational purposes using publicly available information.